Superior Planning, LLC’s Axsome Therapeutics AXSM Stock Holding History

Superior Planning, LLC’s Portfolio AXSM Stock Details AXSM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$5.72K	Buy	+31	New	+$6.74K	﹤0.01%	1146

Other funds holding AXSM

Invesco Atlanta, Georgia $1.27T AUM 50.62% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return

State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $30.6B AUM 42.55% 1-Year Est. Return

Franklin Resources San Mateo, California $474B AUM 32.39% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $170B AUM 38.25% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $71.4B AUM 33.43% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $106B AUM 32.76% 1-Year Est. Return

Superior Planning, LLC's AXSM Position: Q3 2026 in Review

Superior Planning, LLC opened a new position in Axsome Therapeutics (AXSM) in Q3 2026: 31 shares worth $5.72K. The stake represents ﹤0.01% of the portfolio and ranks #1146 among its holdings.

286 funds tracked by Wall St. Rank hold AXSM as of Q3 2026.

Superior Planning, LLC held 31 shares of Axsome Therapeutics worth $5.72K as of Q3 2026.
Axsome Therapeutics was a new Superior Planning, LLC position in Q3 2026.
Axsome Therapeutics made up ﹤0.01% of Superior Planning, LLC's portfolio in Q3 2026, its #1146 holding.
286 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q3 2026.

Based on Superior Planning, LLC's 13F filing for Q3 2026, filed 12 Nov 2026.